Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
- Conditions
- Respiratory Failure
- Interventions
- Registration Number
- NCT04925167
- Lead Sponsor
- Beijing Chao Yang Hospital
- Brief Summary
Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However, many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc seriously affects the prognosis of patients. Argatroban is kind of direct thrombin inhibitors, which could be used used as an alternative anticoagulant of unfractionated heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with unfractionated heparin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- age older than 18 years old; received V-V ECMO because of sevever respiratory failure
- anticoagulant contraindications; Confirmed or suspected, or previously diagnosed with heparin induced thrombocytopenia; Cerebral infarction or suspected patients; Patients with severe liver dysfunction; Allergic to heparin or argatroban; hemophilia; Unwilling or unable to complete the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description UFH group unfractionated heparin Patients received UFH for anticoagulation during V-V ECMO. argatroban group Argatroban Patients received argatroban for anticoagulation during V-V ECMO.
- Primary Outcome Measures
Name Time Method incidence of ECMO related thrombotic events 14 days the incidence of ECMO related thrombotic events, such as membrane oxygenator or tube thrombosis.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bing Sun
🇨🇳Beijing, Beijing, China